Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegfilgrastim prophylaxis during concurrent chemoradiotherapy for head and neck cancer
ChiCTR1800019807Phase 4Recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Jun 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of mecapegfilgrastim in head and neck cancer (HNC), sponsored by Chinese PLA General Hospital. Primary endpoint: Dynamic changes of absolute neutrophil count supported by Jin You Li. Started Jun 2018; status: recruiting.
02
Drugs
mecapegfilgrastim
03
Conditions
head and neck cancer (HNC)
Beyond the preview
Go deeper on ChiCTR1800019807.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800019807.